[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Menarini Silicon Biosystems, INC\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100580173","a-study-for-ctc-expression-and-cfdnarna-assessment-in-metastatic-breast-cancer-patients-100580173",false,"NCT06833853","A Study for CTC Expression and cfDNA\u002FRNA Assessment in Metastatic Breast Cancer Patients","CTC-EXPRESS: A Prospective Observational Study for CTC Expression and cfDNA\u002FRNA Assessment in Metastatic Breast Cancer","CTC-EXPRESS","Inclusion Criteria:\n\n* Invasive breast cancer with radiographic and\u002For clinical evidence of advanced metastatic or unresectable disease.\n* HR+\u002FHER2 negative or triple negative (TN) subjects prior to starting first line therapy or beyond in the metastatic setting.\n\nOR HER2+ subjects prior to starting second line therapy or beyond in the metastatic setting.\n\n* Subject must have the CTC HER2, ER, PD-L1, and cfDNA\u002FRNA tests ordered during routine patient care.\n* Age \\> 18 years.\n\nExclusion Criteria:\n\n* Participant is pregnant.\n* Inability to provide blood samples based on the judgment of the treating physician.","ALL","18 Years",{"count":20,"type":21},187,"ESTIMATED","24 Months","OBSERVATIONAL","The purpose of this research is to learn if the CellSearch Circulating Tumor Cells (CTC) test can help doctors in making decisions about treatment and monitoring of breast cancer. The test consists of diagnostic CTC counts (enumeration) and expression of biomarkers Human Epidermal growth factor Receptor 2 (HER2), Estrogen Receptor (ER), and programmed death-ligand 1 (PD-L1) and cell free DNA\u002FRNA (cfDNA\u002FRNA) analysis.",[26],"Metastatic Breast Cancer (MBC)",[28,29,30],"CTC","cfDNA","cfRNA","RECRUITING","2026-03-16",{"date":34,"type":35},"2026-03-18","ACTUAL",{"date":37,"type":35},"2026-03-13",{"date":39,"type":21},"2028-10",{"name":41,"class":42},"Menarini Silicon Biosystems, INC","INDUSTRY",""]